How can nanotechnology help to combat COVID-19? Opportunities and urgent need
EVR Campos, AES Pereira, JL De Oliveira… - Journal of …, 2020 - Springer
Incidents of viral outbreaks have increased at an alarming rate over the past decades. The
most recent human coronavirus known as COVID-19 (SARS-CoV-2) has already spread …
most recent human coronavirus known as COVID-19 (SARS-CoV-2) has already spread …
Chloroquine against malaria, cancers and viral diseases
Highlights•Chloroquine is used for anti-malaria, anti-cancer and anti-virus treatment.•The
efficacy of hydroxychloroquine against COVID-19 is controversial.•Several quinoline …
efficacy of hydroxychloroquine against COVID-19 is controversial.•Several quinoline …
The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2
NS Ogando, JC Zevenhoven-Dobbe… - Journal of …, 2020 - Am Soc Microbiol
Coronaviruses (CoVs) stand out for their large RNA genome and complex RNA-synthesizing
machinery comprising 16 nonstructural proteins (nsps). The bifunctional nsp14 contains 3 …
machinery comprising 16 nonstructural proteins (nsps). The bifunctional nsp14 contains 3 …
[HTML][HTML] Repurposing anticancer drugs for the management of COVID-19
Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by
SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded …
SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded …
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage
U Ashraf, Z Ding, S Deng, J Ye, S Cao, Z Chen - Virulence, 2021 - Taylor & Francis
Thousands of human deaths occur annually due to Japanese encephalitis (JE), caused by
Japanese encephalitis virus. During the virus infection of the central nervous system …
Japanese encephalitis virus. During the virus infection of the central nervous system …
[HTML][HTML] A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
H Chen, Z Zhang, L Wang, Z Huang, F Gong, X Li… - Medicine, 2020 - journals.lww.com
Methods: This is an open-label, single arm study evaluating the effects of danoprevir
boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time …
boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time …
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication
Coronaviruses rely on host membranes for entry, establishment of replication centers, and
egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways …
egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways …
Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases
The SARS‐CoV‐2 infection cycle is a multistage process that relies on functional
interactions between the host and the pathogen. Here, we repurposed antiviral drugs …
interactions between the host and the pathogen. Here, we repurposed antiviral drugs …
Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases
D Guo - Virologica Sinica, 2020 - Springer
Emerging and re-emerging viral diseases are a public health concern for the whole world
and pose a major threat to human health and life. In last decades, numerous major …
and pose a major threat to human health and life. In last decades, numerous major …